Inulin
Inulin is an unknown pharmaceutical. Inulin was first approved as Inulin and sodium chloride on 1982-01-01.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Inulin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| INULIN AND SODIUM CHLORIDE | Iso-Tex Diagnostics | N-002282 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| jba verestor mega fiber caffe latte | unapproved drug other | 2024-11-11 |
| jba verestor mega fiber powder | unapproved drug other | 2024-11-11 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
346 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | 1 | — | 1 | 19 | 24 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | — | 2 | 11 | 14 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | 2 | 1 | 11 | 14 |
| Constipation | D003248 | — | K59.0 | — | — | — | 2 | 12 | 14 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 2 | 2 | 1 | 2 | 8 | 13 |
| Chronic renal insufficiency | D051436 | — | N18 | 3 | 3 | — | 1 | 5 | 9 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | — | — | 2 | 5 | 8 |
| Dysbiosis | D064806 | — | — | — | — | — | 1 | 7 | 8 |
| Metabolic diseases | D008659 | EFO_0000589 | E88.9 | 1 | — | — | 1 | 5 | 7 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | — | 1 | 6 | 7 |
Show 27 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | U07.1 | 2 | 2 | 6 | — | 4 | 13 |
| Syndrome | D013577 | — | — | — | 1 | 1 | — | 10 | 12 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | 1 | 1 | 1 | — | 7 | 10 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | 2 | 1 | — | 4 | 7 |
| Fatty liver | D005234 | EFO_0003934 | — | 1 | 2 | 1 | — | 3 | 6 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | 1 | 1 | 1 | — | 3 | 5 |
| Diarrhea | D003967 | — | R19.7 | 1 | 1 | 1 | — | 1 | 3 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | 1 | 1 | 2 | — | — | 3 |
| Hyperplasia | D006965 | EFO_0000536 | — | — | — | 1 | — | — | 1 |
| Dietary supplements | D019587 | — | — | — | — | 1 | — | — | 1 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | 1 | — | — | 32 | 34 |
| Infections | D007239 | EFO_0000544 | — | 2 | 3 | — | — | 11 | 15 |
| Inflammation | D007249 | MP_0001845 | — | 1 | 1 | — | — | 10 | 12 |
| Communicable diseases | D003141 | — | — | 1 | 2 | — | — | 10 | 12 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | — | 7 | 8 |
| Microbiota | D064307 | — | — | — | 1 | — | — | 5 | 6 |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | 1 | — | — | 4 | 5 |
| Colorectal neoplasms | D015179 | — | — | 1 | 1 | — | — | 3 | 5 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | 1 | — | — | 2 | 4 |
| Premature birth | D047928 | EFO_0003917 | O60 | 1 | 2 | — | — | 2 | 4 |
Show 41 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Overweight | D050177 | — | E66.3 | 1 | — | — | — | 17 | 18 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | 1 | — | — | — | 6 | 7 |
| Human influenza | D007251 | EFO_0007328 | J11.1 | 2 | — | — | — | 1 | 3 |
| Nutritional and metabolic diseases | D009750 | — | — | 1 | — | — | — | 1 | 2 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 2 | — | — | — | — | 2 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | — | — | — | 1 | 2 |
| Bone diseases | D001847 | — | M89.9 | 1 | — | — | — | — | 1 |
| Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | 1 | — | — | — | — | 1 |
| Endocrine bone diseases | D001849 | — | — | 1 | — | — | — | — | 1 |
| Typhoid fever | D014435 | EFO_0006789 | A01.0 | 1 | — | — | — | — | 1 |
Show 7 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | — | — | — | — | 11 | 11 |
| Healthy diet | D000072001 | — | — | — | — | — | — | 8 | 8 |
| Gastrointestinal microbiome | D000069196 | — | — | — | — | — | — | 6 | 6 |
| Intestinal diseases | D007410 | — | K63.9 | — | — | — | — | 5 | 5 |
| Diet therapy | D004035 | — | — | — | — | — | — | 4 | 4 |
| Dyslipidemias | D050171 | — | — | — | — | — | — | 4 | 4 |
| Bariatric surgery | D050110 | — | — | — | — | — | — | 3 | 3 |
| Digestive signs and symptoms | D012817 | — | — | — | — | — | — | 3 | 3 |
| Appetite | D001066 | — | — | — | — | — | — | 3 | 3 |
| Weight loss | D015431 | — | — | — | — | — | — | 3 | 3 |
Show 132 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Inulin |
| INN | _ |
| Description | Inulins are a group of naturally occurring polysaccharides produced by many types of plants, industrially most often extracted from chicory. The inulins belong to a class of dietary fibers known as fructans. Inulin is used by some plants as a means of storing energy and is typically found in roots or rhizomes. Most plants that synthesize and store inulin do not store other forms of carbohydrate such as starch. In the United States in 2018, the Food and Drug Administration approved inulin as a dietary fiber ingredient used to improve the nutritional value of manufactured food products. Using inulin to measure kidney function is the "gold standard" for comparison with other means of estimating glomerular filtration rate.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 9005-80-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201646 |
| ChEBI ID | — |
| PubChem CID | 24763 |
| DrugBank | DB00638 |
| UNII ID | JOS53KRJ01 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 33,615 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
84 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use